Literature DB >> 20544374

Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005.

Rafael Fuentes-Raspall1, Loreto Vilardell, Ferran Perez-Bueno, Carmen Joly, Maria Garcia-Gil, Adelaida Garcia-Velasco, Rafael Marcos-Gragera.   

Abstract

The purpose of this study was to describe the incidence and survival of primary Central Nervous System (CNS) malignancies using data from the population-based cancer registry for Girona province (north-east Spain).We included all cases of primary CNS malignancies registered between 1994 and 2005. Pathological diagnoses were reviewed and grouped according to the 2007 WHO Classification. Meningeal, soft tissue tumours, spinal cord tumours and primary CNS lymphoma were not included. Cases notified only by death certificate were excluded from the survival analysis. Kaplan and Meier survival curves were calculated from date of diagnosis to death or end of study (31 December 2005), as was relative survival. A total of 493 new CNS cancer patients were registered during the study period: 49.3% astrocytic, 3.4% oligodendroglial and oligoastrocytic tumours, 2.6% ependimal tumours, 3.7% embryonal tumours, 0.2% choroid plexus and 41% without histological confirmation. The mean age (in years) for embryonal tumours was 18.17 years, these being the younger patients in the sample, and 66.34 years for those without histological confirmation, the older patients. Overall, the age standardised incidence rate was 5.88 cases/100,000 people/year (men = 6.81; women = 4.99) with an increasing trend by age until the 70-74 age group. Five-year observed survival rates were: 14.6% for astrocytic tumours, 35.7% for oligodendroglial and oligoastrocytic tumours, 41.0% for ependymal tumours, 32.4% for embryonal tumours and 7.5% for those without histological confirmation (log rank test: P < 0.001). Five-year observed survival rates for astrocytic tumours were analyzed separately by tumour grading, with 37% for diffuse astrocytoma, 7.1% for anaplastic astrocytoma and 4.7% for glioblastoma (log rank test: P < 0.001).Our results show that astrocytic tumours are most frequently diagnosed and glioblastoma patients have the worst survival figures for the area covered by our population cancer registry.The high observed incidence of histologically unverified tumours is most probably due to easy access to state of the art CNS imaging in our area.

Entities:  

Mesh:

Year:  2010        PMID: 20544374     DOI: 10.1007/s11060-010-0240-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  From expert opinion to evidence-based: changes in the gold standard of primary brain tumour diagnosis.

Authors:  J M Kros
Journal:  J Pathol       Date:  2007-09       Impact factor: 7.996

2.  WAERS: an application for Web-assisted estimation of relative survival.

Authors:  Ramon Clèries; Joan Valls; Laura Esteban; Jordi Gálvez; Laura Pareja; Xavier Sanz; Luisa Alliste; José Miguel Martínez; Víctor Moreno; Xavier Bosch; Josep Maria Borràs; Josepa Maria Ribes
Journal:  Med Inform Internet Med       Date:  2007-09

Review 3.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

4.  On long-term relative survival rates.

Authors:  T Hakulinen
Journal:  J Chronic Dis       Date:  1977-07

5.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

Authors:  Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

6.  Neoplasms of the central nervous system in Norway. III. Epidemiological characteristics of intracranial gliomas according to histology.

Authors:  A Helseth; S J Mørk
Journal:  APMIS       Date:  1989-06       Impact factor: 3.205

7.  Descriptive epidemiology of cerebral gliomas in France.

Authors:  A Fleury; F Menegoz; P Grosclaude; J P Daures; M Henry-Amar; N Raverdy; P Schaffer; M Poisson; J Y Delattre
Journal:  Cancer       Date:  1997-03-15       Impact factor: 6.860

8.  Incidence of primary intracranial neoplasms in an isolated population (the Faroese) during the period 1962-1975.

Authors:  P Joensen
Journal:  Acta Neurol Scand       Date:  1981-07       Impact factor: 3.209

9.  Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma.

Authors:  Jill S Barnholtz-Sloan; Vonetta L Williams; John L Maldonado; Dilip Shahani; Heather G Stockwell; Marc Chamberlain; Andrew E Sloan
Journal:  J Neurosurg       Date:  2008-04       Impact factor: 5.115

10.  The incidence of intracranial gliomas in southern Finland.

Authors:  M Kallio
Journal:  Acta Neurol Scand       Date:  1988-12       Impact factor: 3.209

View more
  11 in total

1.  Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences.

Authors:  Daniel Ruiz-Sánchez; Irene Iglesias Peinado; Miguel Alaguero-Calero; Alejandro José Sastre-Heres; Benito García Diez; Jaime Peña-Díaz
Journal:  Oncol Lett       Date:  2016-07-15       Impact factor: 2.967

2.  Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.

Authors:  C Balañá; M A Vaz; D Lopez; R de la Peñas; J M García-Bueno; M J Molina-Garrido; J M Sepúlveda; J M Cano; C Bugés; S M Sanz; J L Arranz; P Perez-Segura; A Rodriguez; J M Martin; M Benavides; M Gil
Journal:  Clin Transl Oncol       Date:  2013-06-21       Impact factor: 3.405

3.  Trends in the Management Paradigms of Intracranial Meningioma.

Authors:  Zaid Aljuboori; Ahmad Alhourani; Shiao Woo; Eyas Hattab; Mehran Yusuf; Megan Nelson; Norberto Andaluz; Dale Ding; Jesse Savage; Brian Williams
Journal:  J Neurol Surg B Skull Base       Date:  2019-09-17

4.  Primary brain tumour epidemiology in Georgia: first-year results of a population-based study.

Authors:  David Gigineishvili; Nino Shengelia; Giorgi Shalashvili; Sabine Rohrmann; Alexander Tsiskaridze; Roman Shakarishvili
Journal:  J Neurooncol       Date:  2013-01-21       Impact factor: 4.130

5.  Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis.

Authors:  Albert Pons-Escoda; Alonso Garcia-Ruiz; Pablo Naval-Baudin; Francesco Grussu; Juan Jose Sanchez Fernandez; Angels Camins Simo; Noemi Vidal Sarro; Alejandro Fernandez-Coello; Jordi Bruna; Monica Cos; Raquel Perez-Lopez; Carles Majos
Journal:  Eur Radiol       Date:  2022-02-01       Impact factor: 5.315

6.  Temporal evolution of brain cancer incidence in the municipalities of Navarre and the Basque Country, Spain.

Authors:  María Dolores Ugarte; Aritz Adin; Tomás Goicoa; Itziar Casado; Eva Ardanaz; Nerea Larrañaga
Journal:  BMC Public Health       Date:  2015-10-05       Impact factor: 3.295

7.  Incidence rates of the primary brain tumours in Georgia--a population-based study.

Authors:  David Gigineishvili; Teimuraz Gigineishvili; Alexander Tsiskaridze; Roman Shakarishvili
Journal:  BMC Neurol       Date:  2014-02-14       Impact factor: 2.474

8.  Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.

Authors:  Liang Xia; Bin Wu; Zhiquan Fu; Fang Feng; Enqi Qiao; Qinglin Li; Caixing Sun; Minghua Ge
Journal:  Oncotarget       Date:  2015-07-10

9.  Increasing incidence of central nervous system (CNS) tumors (2000-2012): findings from a population based registry in Gironde (France).

Authors:  Camille Pouchieu; Anne Gruber; Emilie Berteaud; Patrice Ménégon; Pascal Monteil; Aymeri Huchet; Jean-Rodolphe Vignes; Anne Vital; Hugues Loiseau; Isabelle Baldi
Journal:  BMC Cancer       Date:  2018-06-14       Impact factor: 4.430

10.  Geographical variation in malignant and benign/borderline brain and CNS tumor incidence: a comparison between a high-income and a middle-income country.

Authors:  Miriam Wanner; Sabine Rohrmann; Dimitri Korol; Nino Shenglia; Teimuraz Gigineishvili; David Gigineishvili
Journal:  J Neurooncol       Date:  2020-08-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.